5021 Everolimus (RAD001) in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab: a multicenter phase I clinical trial

Published 2009 View Full Article

Authors

Keywords

Journal

EJC SUPPLEMENTS

Volume 7, Issue 2, Pages 267

Publisher

Elsevier BV

Online

2009-09-03

DOI

10.1016/s1359-6349(09)70913-9

Ask authors/readers for more resources

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

EJC SUPPLEMENTS

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Publish scientific posters with Peeref

Become a Peeref-certified reviewer